While some of the countries are fearing a second wave of Coronavirus with the number of cases increasing with time, it seems like we might have some good news as Pfizer and BioNTech have recently announced that their vaccine is proven to be 95 percent effective and more advancement is on its way.
Pfizer And BioNTech Have Some New Development On The Vaccine.
CEO Albert Bourla has further stated that it now has the median two-month follow-up data needed to secure EUA from the FDA. This will enable it to be a step closer to bringing its vaccine to market in the U.S. This will be hugely helpful assume countries are looking at an unwanted rise in the number of COVID cases. In such a scenario, an effective vaccine might do the wonders that the whole world needs so badly in the face of such a huge health crisis. Here is the recent update that have been posted on the official page of the company.
BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints.
— Pfizer Inc. (@pfizer) November 18, 2020
While the companies have been opening up about the advancement for quite a while bow, it was recently stated that the vaccine is 95 percent effective in the phase three trial. Bourla has earlier also said that the advancements are looking positive enough and it indeed is a great day for science and humanity.
Ongoing coordination is critical to help ensure efficient vaccine distribution as soon as possible if our vaccine candidate receives authorization or approval. Thank you @GregAbbott_Tx for helping as we prepare to create effective immunization programs.
— AlbertBourla (@AlbertBourla) November 18, 2020
The CEO Of Pfizer Has Been Giving Us New Updates.
While the advancement and growth of the vaccine look impressive enough, it will take a bit more time for the key question of vaccine durability to be answered in the coming weeks. It will also be the first company to seek with EUA. However, Moderna is also closely behind as well. So, it might be arriving soon after all.
Within days, we plan to submit a request to the @US_FDA for an EUA based on the totality of safety and efficacy data collected, as well as manufacturing data relating to the quality and consistency of the vaccine candidate.
— Pfizer Inc. (@pfizer) November 18, 2020